Previous 10 | Next 10 |
The following slide deck was published by Jazz Pharmaceuticals plc in conjunction with this event. For further details see: Jazz Pharmaceuticals (JAZZ) Presents at the Needham Virtual Neuroscience Forum - Slideshow
Jazz Pharmaceuticals to Present Pan-RAF Inhibitor Pre-Clinical Data at American Association for Cancer Research (AACR) 2022 Annual Meeting PR Newswire DUBLIN , March 8, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that pre-clinical...
This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...
Shares of the mid-cap biotech Jazz Pharmaceuticals (NASDAQ: JAZZ) were up by 12.2% as of 1:19 p.m. ET on Wednesday. The drugmaker's stock is up today in response to its better-than-expected 2021 fourth-quarter and full-year results. What's the main impetus behind today's dou...
Jazz Pharmaceuticals (JAZZ +12.1%) has recorded the biggest intraday gain since 2017 on Wednesday to reach a six-month high on the strong Q4 earnings beat reported by the Neuroscience-focused biopharmaceutical company yesterday. Jazz (NASDAQ:JAZZ) reported more than $3B annual revenue for the...
The following slide deck was published by Jazz Pharmaceuticals plc in conjunction with their 2021 Q4 earnings call. For further details see: Jazz Pharmaceuticals plc 2021 Q4 - Results - Earnings Call Presentation
Jazz Pharmaceuticals plc (JAZZ) Q4 2021 Earnings Conference Call March 1, 2022 4:30 PM ET Company Participants Andrea Flynn - VP & Head, IR Bruce Cozadd - Co-Founder, Chairman & CEO Daniel Swisher - President Robert Iannone - EVP, Research & Development & Chief Medical Officer...
Jazz Pharmaceuticals press release (NASDAQ:JAZZ): Q4 Non-GAAP EPS of $4.21 beats by $0.58. Revenue of $896.73M (+34.7% Y/Y) beats by $30.02M. Shares -1.05%. Growing and durable commercial franchises drove 2021 total revenues of $3.1 billion; 31% increase compared to 2020 Significant deleverag...
JAZZ PHARMACEUTICALS ANNOUNCES FULL YEAR AND FOURTH QUARTER 2021 FINANCIAL RESULTS PR Newswire DUBLIN , March 1, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2021 and provid...
Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences Cowen Health Care Conference Needham Virtual Neuroscience Forum PR Newswire DUBLIN , Feb. 28, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the ...
News, Short Squeeze, Breakout and More Instantly...
Jazz Pharmaceuticals plc Company Name:
JAZZ Stock Symbol:
NASDAQ Market:
Jazz Pharmaceuticals plc Website:
Jazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance PR Newswire – 15% year-over-year revenue increase from combined key growth drivers: Xywav ® , Epidiolex ® and Rylaze ® – – O...
Jazz Pharmaceuticals Shareholders Elect Laura Hamill to the Company's Board of Directors at Annual General Meeting PR Newswire Ms. Hamill brings extensive experience and proven leadership focused on commercial growth and shareholder value DUBLIN , July 25, 20...
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / Jazz Pharmaceuticals Originally published by Jazz Pharmaceuticals In celebration of Pride Month , we were joined by Celia Sandhya Daniels (she/they) who led an insightful discussion aimed at educating, raising awareness and calling for unders...